Literature DB >> 27542512

The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer: A Report of the Association for Molecular Pathology.

Loren Joseph1, Milena Cankovic2, Samuel Caughron3, Pranil Chandra4, Rajyasree Emmadi5, Jill Hagenkord6, Stephanie Hallam7, Kay E Jewell8, Roger D Klein9, Victoria M Pratt10, Paul G Rothberg11, Robyn L Temple-Smolkin12, Elaine Lyon13.   

Abstract

Clinical utility describes the benefits of each laboratory test for that patient. Many stakeholders have adopted narrow definitions for the clinical utility of molecular testing as applied to targeted pharmacotherapy in oncology, regardless of the population tested or the purpose of the testing. This definition does not address all of the important applications of molecular diagnostic testing. Definitions consistent with a patient-centered approach emphasize and recognize that a clinical test result's utility depends on the context in which it is used and are particularly relevant to molecular diagnostic testing because of the nature of the information they provide. Debates surrounding levels and types of evidence needed to properly evaluate the clinical value of molecular diagnostics are increasingly important because the growing body of knowledge, stemming from the increase of genomic medicine, provides many new opportunities for molecular testing to improve health care. We address the challenges in defining the clinical utility of molecular diagnostics for inherited diseases or cancer and provide assessment recommendations. Starting with a modified analytic validity, clinical validity, clinical utility, and ethical, legal, and social implications model for addressing clinical utility of molecular diagnostics with a variety of testing purposes, we recommend promotion of patient-centered definitions of clinical utility that appropriately recognize the valuable contribution of molecular diagnostic testing to improve patient care.
Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27542512     DOI: 10.1016/j.jmoldx.2016.05.007

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  22 in total

1.  Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab.

Authors:  Emil Lou; Donna D'Souza; Andrew C Nelson
Journal:  J Natl Compr Canc Netw       Date:  2017-04       Impact factor: 11.908

Review 2.  Preparing pathology for precision medicine: challenges and opportunities.

Authors:  Karen L Kaul
Journal:  Virchows Arch       Date:  2017-05-16       Impact factor: 4.064

Review 3.  Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.

Authors:  Lawrence J Jennings; Maria E Arcila; Christopher Corless; Suzanne Kamel-Reid; Ira M Lubin; John Pfeifer; Robyn L Temple-Smolkin; Karl V Voelkerding; Marina N Nikiforova
Journal:  J Mol Diagn       Date:  2017-03-21       Impact factor: 5.568

4.  How Can Law and Policy Advance Quality in Genomic Analysis and Interpretation for Clinical Care?

Authors:  Barbara J Evans; Gail Javitt; Ralph Hall; Megan Robertson; Pilar Ossorio; Susan M Wolf; Thomas Morgan; Ellen Wright Clayton
Journal:  J Law Med Ethics       Date:  2020-03       Impact factor: 1.718

5.  The need to develop a patient-centered precision medicine model for adults with chronic disability.

Authors:  Susan M Wolf; Bharat Thyagarajan; Brent L Fogel
Journal:  Expert Rev Mol Diagn       Date:  2017-04-03       Impact factor: 5.225

Review 6.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.

Authors:  Marilyn M Li; Michael Datto; Eric J Duncavage; Shashikant Kulkarni; Neal I Lindeman; Somak Roy; Apostolia M Tsimberidou; Cindy L Vnencak-Jones; Daynna J Wolff; Anas Younes; Marina N Nikiforova
Journal:  J Mol Diagn       Date:  2017-01       Impact factor: 5.568

7.  Barriers and Facilitators for Population Genetic Screening in Healthy Populations: A Systematic Review.

Authors:  Emily C Shen; Swetha Srinivasan; Lauren E Passero; Caitlin G Allen; Madison Dixon; Kimberly Foss; Brianna Halliburton; Laura V Milko; Amelia K Smit; Rebecca Carlson; Megan C Roberts
Journal:  Front Genet       Date:  2022-07-04       Impact factor: 4.772

Review 8.  The role of genomics in global cancer prevention.

Authors:  Ophira Ginsburg; Paul Brennan; Patricia Ashton-Prolla; Anna Cantor; Daniela Mariosa
Journal:  Nat Rev Clin Oncol       Date:  2020-09-24       Impact factor: 66.675

9.  Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.

Authors:  Jennifer A Oberg; Julia L Glade Bender; Maria Luisa Sulis; Danielle Pendrick; Anthony N Sireci; Susan J Hsiao; Andrew T Turk; Filemon S Dela Cruz; Hanina Hibshoosh; Helen Remotti; Rebecca J Zylber; Jiuhong Pang; Daniel Diolaiti; Carrie Koval; Stuart J Andrews; James H Garvin; Darrell J Yamashiro; Wendy K Chung; Stephen G Emerson; Peter L Nagy; Mahesh M Mansukhani; Andrew L Kung
Journal:  Genome Med       Date:  2016-12-23       Impact factor: 11.117

10.  Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing.

Authors:  Scott Newman; Joy Nakitandwe; Chimene A Kesserwan; Elizabeth M Azzato; David A Wheeler; David W Ellison; James R Downing; Jinghui Zhang; Kim E Nichols; Michael Rusch; Sheila Shurtleff; Dale J Hedges; Kayla V Hamilton; Scott G Foy; Michael N Edmonson; Andrew Thrasher; Armita Bahrami; Brent A Orr; Jeffery M Klco; Jiali Gu; Lynn W Harrison; Lu Wang; Michael R Clay; Annastasia Ouma; Antonina Silkov; Yanling Liu; Zhaojie Zhang; Yu Liu; Samuel W Brady; Xin Zhou; Ti-Cheng Chang; Manjusha Pande; Eric Davis; Jared Becksfort; Aman Patel; Mark R Wilkinson; Delaram Rahbarinia; Manish Kubal; Jamie L Maciaszek; Victor Pastor; Jay Knight; Alexander M Gout; Jian Wang; Zhaohui Gu; Charles G Mullighan; Rose B McGee; Emily A Quinn; Regina Nuccio; Roya Mostafavi; Elsie L Gerhardt; Leslie M Taylor; Jessica M Valdez; Stacy J Hines-Dowell; Alberto S Pappo; Giles Robinson; Liza-Marie Johnson; Ching-Hon Pui
Journal:  Cancer Discov       Date:  2021-12-01       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.